



MaaT Pharma to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

Lyon, France, January 3, 2022 - 7:00 pm CET – **MaaT Pharma** (EURONEXT: MAAT - the “Company”), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer, announced today that its CEO and co-founder, Hervé Affagard will present the company at the upcoming H.C. Wainwright Bioconnect Virtual Conference held January 10-13, 2022.

The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at **7 am EST/1:00 pm CET on Monday, January 10, 2022.**

A replay of the presentation will also be made accessible in the [investors' section](#) of the company's website at www.maatpharma.com from Friday, January 14, 2022 and for 90 days after the event.

About MaaT Pharma

MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in a Phase II clinical trial in acute GvHD. Our powerful discovery and analysis platform, gutPrint®, supports the development and expansion of our pipeline by determining novel disease targets, evaluating drug candidates, and identifying biomarkers for microbiome-related conditions.

The company's Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice.

MaaT Pharma is listed on Euronext Paris (ticker: MAAT).

Contacts

MaaT Pharma
Hervé AFFAGARD
Co-Founder and CEO
Siân Crouzet – COO/CFO
+33 4 28 29 14 00
invest@maat-pharma.com

MaaT Pharma
Pauline RICHAUD
PR and Corporate
Communications Manager
+33 6 07 55 25 36
prichaud@maat-pharma.com

Trophic Communications
Corporate and medical
Communications
Jacob VERGHESE or
Gretchen SCHWEITZER
+49 89 23 88 77 31
maat@trophic.eu